Skip to main content Skip to section navigation Skip to footer

XORTX Therapeutics Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Advisory Board
  • Pipeline
    • Overview
    • XRx-008 for Autosomal Dominant Polycystic Kidney Disease
    • XRx-101 for Coronavirus/COVID-19
    • XRX-225 for Type 2 Diabetic Nephropathy
    • Publications
  • Technology
  • News & Media
    • Press Releases
    • Events
    • In the News
  • Investors
    • Overview
    • News & Events
    • Presentations
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • SEDAR
    • Governance
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Annual & Special Meeting of Shareholders
    • Email Alerts
  • Presentations
  • Company Info
    • Overview
    • Management Team
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
  • Stock Data
    • Analyst Coverage
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • SEDAR
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Board Diversity Matrix
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Annual & Special Meeting of Shareholders
  • Email Alerts
Mar 14, 2023 7:00am EDT

XORTX Announces Type D Meeting with FDA to be held May 1, 2023

Feb 07, 2023 7:00am EST

XORTX Provides Update on 2022 Achievements and 2023 Planned Milestones

Feb 01, 2023 7:00am EST

XORTX Announces Submission of Orphan Drug Designation Request for XRx-008 Program to Treat Autosomal Dominant Kidney Disease

Jan 19, 2023 7:00am EST

XORTX Announces Positive Topline Results from XRX-OXY-101 Clinical Trial

Jan 03, 2023 7:00am EST

XORTX Files New Provisional Patent to Diagnose and Treat Individuals Most at Risk of Polycystic Kidney Disease Progression

Dec 19, 2022 7:00am EST

XORTX Announces Completion of Dosing in XRX-OXY-101 Clinical Study

Dec 08, 2022 7:00am EST

XORTX Announces New Proof of Concept Data in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Nov 28, 2022 7:00am EST

XORTX Announces Completion of Screening and Enrollment in Bridging Pharmacokinetics Study

Nov 25, 2022 5:45pm EST

XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

Nov 16, 2022 7:00am EST

XORTX Therapeutics Appoints Stacy Evans, M.D., MBA as Chief Business Officer

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • …12
  • arrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
©2023 XORTX Therapeutics Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap